Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma

Effect of Fenoterol Metered Dose Inhaler (0.1 mg) on the Beta-receptor Population on Lymphocytes and the Clinical Findings Compared With Treatment With DSCG Metered Dose Inhaler in Patients With Bronchial Asthma.

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02177370

Enrollment

Registered

2014-06-27

Start date

1990-02-28

Completion date

Unknown

Last updated

2014-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Brief summary

The aim of the study was to compare the effect of fenoterol metered dose inhaler with disodium cromoglycate (DSCG) metered dose inhaler on the lymphocyte β2-receptor population as well as on the clinical findings in patients with bronchial asthma over a two-week period of treatment.

Interventions

DRUGFenoterol MDI

DRUGDSCG MDI

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* sex: male and female * age: 18 years or over * bronchial asthma, diagnosis confirmed by history and positive inhalation challenge test (unspecific challenge with carbachol, PD100SRaw)) * severity of asthma mild to moderate or asthmatic in symptom-free intervals * Raw ≤ 5 cm H2O/l/s * no antiasthmatic treatment in the week (steroid therapy: two weeks) before the start of the study

Exclusion criteria

* clinically significant, concomitant haematological, cardiac, renal, hepatic or metabolic diseases * intercurrent diseases, e.g. severe respiratory infections * patients who cannot do without the following preparations during the 5-week trial: * inhaled/oral steroids * theophylline * antihistamine, antiallergic drugs * inhaled/oral sympathomimetics * anticholinergics

Design outcomes

Primary

Measure	Time frame
Airway resistance (Raw)	after 2 weeks
Number of binding sites of the β2 receptors per lymphocytes (BS/LY)	after 2 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026